BlossomHill Therapeutics, Inc. (Ticker: BLSM US) is an American clinical-stage biotechnology company developing new cancer treatments. Its research focuses on medicines designed to target genetic changes that help certain cancers grow, including forms of lung cancer, leukemia and other tumors that can be difficult to treat.

BlossomHill plans to list on Nasdaq on August 7, 2026, following expected pricing on August 6. The company is offering 7,812,500 newly issued shares at a price of $15.00 to $17.00 per share. At the midpoint of the range, the IPO would raise approximately $125 million. Because all shares are primary, the proceeds will go to the company rather than existing shareholders.

The company’s most advanced drug candidates are being studied for a type of lung cancer that has become resistant to existing treatments, as well as for certain blood cancers. BlossomHill also has an earlier-stage drug candidate aimed at tumors linked to KRAS mutations, which are common genetic drivers in several cancers.

BlossomHill previously raised $100 million in a Series B financing. J.P. Morgan, Leerink Partners and Guggenheim are serving as bookrunners.